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SUMMARY: 
Co-inheritance of germline mutation in cyclin-dependent kinase inhibitor 2A (CDKN2A) and loss-
of-function (LOF) melanocortin 1 receptor (MC1R) variants is clinically associated with exaggerated risk 
for melanoma. To understand the combined impact of these mutations, we established and tested primary 
human melanocyte cultures from V126D, 32ins24, or 5’UTR-34G>T CDKN2A mutation carriers, 
expressing either wild-type MC1R or MC1R LOF variant(s). These cultures expressed the CDKN2A 
product p16 (INK4A) and functional MC1R. Except for 32ins24 mutant melanocytes, the remaining 
cultures showed no detectable aberrations in proliferation or capacity for replicative senescence. 
Additionally, the latter cultures responded normally to ultraviolet radiation (UV) by cell cycle arrest, 
JNK, p38, and p53 activation, hydrogen peroxide generation, and repair of DNA photoproducts. We 
propose that malignant transformation of melanocytes expressing CDKN2A mutation and MC1R LOF 
allele(s) requires acquisition of somatic mutations facilitated by MC1R genotype or aberrant 
microenvironment due to CDKN2A mutation in keratinocytes and fibroblasts. 
 
 
Abbreviations: CDKN2A=Cyclin-dependent kinase inhibitor 2 A; Rb=Retinoblastoma protein; 
MC1R=Melanocortin 1 receptor; LOF=Loss of function; α-MSH=α-Melanocyte stimulating hormone; 
UV=Ultraviolet radiation; cAMP=Cyclic adenosine monophosphate; CDK=Cyclin-dependent kinase; 
CPD=Cyclobutane pyrimidine dimers 
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SIGNIFICANCE: 
Epidemiological evidence shows that co-inheritance of germline CDKN2A mutation and loss-of-
function MC1R variant exacerbates the risk for melanoma above that resulting from mutation in either 
gene. To investigate the mechanism for this increased risk, we established primary human melanocyte 
cultures from CDKN2A mutation carriers who expressed either wild-type or LOF MC1R variant(s). 
Except for 32ins24 CDKN2A mutation, we found no detectable differences in the in vitro behavior or 
response to UV of these melanocytes. We propose that co-inheritance of CDKN2A and MC1R mutations 
exaggerates melanoma risk by promoting the mutator phenotype of melanocytes possibly by an aberrant 
cutaneous microenvironment.  
 
Key words:  
CDKN2A, MC1R, proliferation, replicative senescence, ultraviolet radiation 
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INTRODUCTION: 
Two important melanoma predisposition genes are CDKN2A and melanocortin 1 receptor gene 
(MC1R). Germline mutations in CDKN2A are the most prevalent in familial melanoma pedigrees, and 
also increase the risk for other malignancies, such as pancreas, lung, and breast cancers (de Snoo et al., 
2008; Goldstein et al., 2006). These mutations occur in less than 2% of all melanoma cases, yet are highly 
penetrant, increasing the lifetime risk of melanoma by 67% (Bishop et al., 2002). Loss-of-function 
variants of MC1R (namely R151C, R160W, and D294H, designated as R alleles), associated with red hair 
phenotype, poor tanning ability and increased risk for melanoma, are more common but less penetrant 
than CDKN2A mutations (Box, Wyeth, O'Gorman, Martin, & Sturm, 1997; Kadekaro et al., 2010; Smith 
et al., 1998). Twenty-four percent of melanoma patients carry MC1R LOF variants, and although 
redheads who express two MC1R LOF alleles comprise only 1-2% of the worldwide population, they 
represent 16% of all melanoma patients (Olsen, Carroll, & Whiteman, 2010; Williams, Olsen, Hayward, 
& Whiteman, 2011).   
CDKN2A and MC1R serve important functions to preserve the genomic stability of melanocytes. 
The tumor suppressor p16 INK4A (p16), one product of the CDKN2A locus, is a cyclin-dependent kinase 
(CDK) 4/6 inhibitor, which causes G1 arrest by activating the retinoblastoma (Rb) protein and 
suppressing the transcription factor E2F1 (Chicas et al., 2010; Sun, Bagella, Tutton, Romano, & 
Giordano, 2007). An important function of p16, particularly in melanocytes, is regulation of senescence 
(Fung, Pupo, Scolyer, Kefford, & Rizos, 2013; Haferkamp et al., 2009; Rayess, Wang, & Srivatsan, 2012; 
Sviderskaya et al., 2003). Additionally, mutations in CDKN2A seem to reduce nucleotide excision repair 
capacity and contribute to oxidative stress (Jenkins et al., 2011; Sarkar-Agrawal, Vergilis, Sharpless, 
DePinho, & Runger, 2004) . The MC1R codes for a Gs protein-coupled receptor that is expressed on the 
cell surface of melanocytes (Abdel-Malek et al., 2014; Abdel-Malek et al., 1995). Activation of the 
MC1R by its agonist α-melanocyte stimulating hormone (α-MSH) stimulates eumelanin synthesis, 
reduces ultraviolet radiation (UV)-induced generation of reactive oxygen species and enhances DNA 
repair in human melanocytes (Kadekaro et al., 2010; Song et al., 2009; Swope et al., 2014). An additional 
mechanism by which the activated MC1R prevents the genotoxic effects of UV is by inhibiting the 
degradation of the tumor suppressor PTEN, thereby leading to inactivation of the phosphatidylinositol 3 
kinase/Akt oncogenic pathway (Cao et al., 2013). 
Multiple epidemiological studies reported that co-inheritance of a mutant CDKN2A and MC1R 
LOF variant exacerbates melanoma risk and results in early onset of melanoma (Box et al., 2001; 
Demenais et al., 2010; Fargnoli, Gandini, Peris, Maisonneuve, & Raimondi, 2010; Goldstein et al., 2005). 
CDKN2A mutation carriers with one MC1R variant showed a double melanoma risk as compared to 
CDKN2A mutation carriers expressing wild type MC1R (Fargnoli et al., 2010).  This led us to compare 
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the in vitro behavior of primary human melanocyte cultures established from skin biopsies of members of 
three familial melanoma kindreds who are carriers of  one of 3 known deleterious CDKN2A mutations, 
and expressing either wild type or LOF MC1R variant(s),  and of those established from donors 
expressing wild-type for CDKN2A and similar MC1R genotype (Table 1). We focused on investigating 
cultured melanocytes, given that they are the skin cells most drastically affected by CDKN2A mutations 
or MC1R variants. The endpoints we examined were: expression of p16, INK4B (p15), and Rb proteins, 
proliferation rate, capacity for replicative senescence, and various aspects of the DNA damage response to 
UV. In vitro, melanocytes heterozygous for V126D or 5’UTR-34G>T mutation, even those carrying 
MC1R LOF allele(s), were similar to their CDKN2A wild-type counterparts in all these parameters. Our 
results confirm that malignant transformation of CDKN2A mutant and MC1R variant melanocytes 
requires accumulation of additional “hits”, such as somatic mutations in genes that regulate proliferation 
or apoptosis, as reported (Bennett, 2016). Expression of MC1R LOF variants increases the chance for 
somatic mutations that drive melanomagenesis (Robles-Espinoza et al., 2016). It is also conceivable that 
CDKN2A germline mutations in keratinocytes and fibroblasts result in an aberrant microenvironment that 
promotes melanocyte transformation. Our results underscore the importance of investigating the impact of 
co-inheritance of CDKN2A and MC1R mutations on melanocytes in the context of the skin as an organ. 
We have established from the same cohort primary keratinocyte and fibroblast cultures that we will use to 
investigate the impact of CDKN2A genotype on their secretome, and to develop 3D skin models to 
address how the cutaneous microenvironment might affect the genomic stability of melanocytes.  
 
MATERIALS AND METHODS: 
Establishment of primary melanocyte cultures and UV irradiation: 
 Primary adult human melanocyte cultures were established from skin biopsies of members of 
familial melanoma kindreds, or other patients of the Huntsman Cancer Institute Melanoma Clinic in Utah, 
after informed consent (IRB protocol; # 7916). Other cultures were established from surgical discards of 
adult skin or from neonatal foreskins. All of these cultures were maintained in our previously described 
routine melanocyte growth medium (Abdel-Malek et al., 1995). However, the cultures 13a and 14a failed 
to proliferate in this medium, and required a more enriched growth medium in order to replicate, as 
described earlier (Sviderskaya et al., 2003). The enriched medium consisted of MCDB 153, 2% fetal 
bovine serum, 5 µg/ml insulin, 0.5 µg/ml hydrocortisone, 28 µg/ml bovine pituitary extract, 1 nM 
endothelin-1, and 1 ng/ml basic fibroblast growth factor. The cultures were authenticated by 
immunostaining for the melanocyte-specific marker TRP-1. Penicillin/streptomycin and antimycotics, as 
well as plasmocin, were added routinely to the culture media. For experiments involving UV exposure, 
melanocytes were irradiated with a dose of 75 or 90 mJ/cm2 UV, as described (Kadekaro et al., 2010). 
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cAMP measurement:  
 The levels of cAMP were determined using a radioimmunoassay, as described (Suzuki, Cone, Im, 
Nordlund, & Abdel-Malek, 1996). 
Determination of doubling time:  
 Melanocytes were plated in 6-well plates at a density of 0.15x106 cells/well (day 0). To determine 
the effect of UV on proliferation, melanocytes were irradiated with a sublethal dose of 75 mJ/cm2 UV on 
day 3. Medium was changed, and cell numbers in the control and UV-irradiated groups were determined 
on day 3, and every other day thereafter, for 10 more days (n=3 wells/time point). The doubling times 
were calculated from the slope of the growth curve. 
Cell cycle analysis:  
 Melanocytes were plated at a density of 0.3x106 cells/60 mm dish. On day 3 after plating, cells 
were irradiated with 0 (control) or 75 mJ/cm2 UV, and fresh medium was added thereafter. Cell cycle 
analysis was performed at 0, 6, 24, 48, and 72 h after UV as described (von Koschembahr, Swope, 
Starner, & Abdel-Malek, 2015).  
β-galactosidase staining:  
 Melanocytes were plated at a density of 2x104 cells/well in an 8-well chamber slide (4 
wells/group). After 3 days, cells were stained using a commercially available kit (Cell Signaling). 
Microscopic images were acquired, the percent of β-galactosidase positive melanocytes were quantified, 
and the data expressed as mean ± SEM. At least 500 melanocytes were analyzed/group. 
Quantitation of cyclobutane pyrimidine dimers (CPD):  
 Melanocytes were plated at 0.3x106 cells/60 mm dish, and irradiated 3 days thereafter with 0 
(control) or 90 mJ/cm2 UV, a dose that results in extensive DNA damage, but moderate apoptosis 
(≤20%).  At least triplicate dishes were included in each group. In some experiments, melanocytes were 
treated with α-MSH prior to, and post UV-irradiation, as described (Kadekaro et al., 2010). Three, and 48 
h post UV, melanocytes were harvested and fixed, immunostained with CPD-specific antibody 
(CosmoBio), and analyzed by flow cytometry, as described (Kadekaro et al., 2010). 
Measurement of hydrogen peroxide:  
 Melanocytes were plated and irradiated with 90 mJ/cm2 UV. Generation of hydrogen peroxide 
was determined at 0, 30, and 60 min post UV as described (Song et al., 2009). 
Western blot analysis:  
 For detection of p16, p15, and p-Rb, melanocytes were plated at a density of 0.75-1x106 in 100 
mm dishes. Three days thereafter, fresh medium was added, and 24 h later, cells were lysed using RIPA 
buffer containing protease and phosphatase inhibitors. Western blotted proteins were detected using 
specific antibodies for p16 or p15 (Abcam; Cambridge, MA), and p-Rb (Cell Signaling, Danvers, MA). 
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For detection of p- and total JNK and p38, p-Rb, p53 and GADD45α, melanocytes were plated as above, 
irradiated with 0 (control) or 75 mJ/cm2 UV, and cell lysates prepared at 0.5,1.5, 4, 6, and 24 h. Phospho- 
and total JNK and p38 antibodies were purchased from Cell Signaling, and p53 and GADD45α antibodies  
were obtained from Santa Cruz Biotechnology (Dallas, TX).  
 
RESULTS AND DISCUSSION: 
Expression of p16, Rb, and p15, and MC1R activity in cultured melanocytes:  
We established primary human melanocyte cultures from members of three familial melanoma 
pedigrees who are heterozygous for the CDKN2A mutation V126D and expressing either wild-type or 
MC1R LOF variant R151C, R160W, and D294H, or heterozygous for CDKN2A 5’UTR-34G>T or 
32ins24 mutation and LOF MC1R variant, or V60L, a variant associated with blonde hair and modest 
increase in melanoma risk (Box et al., 1997; Kadekaro et al., 2010; Smith et al., 1998).  The CDKN2A 
V126D mutation in exon 2 creates a temperature-sensitive protein that binds to CDK4 efficiently at the 
permissive temperature of 34oC (Goldstein et al., 2001; Parry & Peters, 1996). The 5’UTR-34G>T 
mutation in exon 1 introduces an alternative translational start site that was reported to reduce expression 
of the wild-type protein (Liu et al., 1999). The 32ins24 mutation in exon 1 codes for a protein containing 
8 additional amino acids (Eliason et al., 2006). These mutations are deleterious, and do not affect 
expression of p14 ARF, the second CDKN2A product (Goldstein et al., 2006). For all experiments, with 
exception of 13a and 14a, all cultures were maintained in the same routine melanocyte growth medium 
(Abdel-Malek et al., 1995). 
Except for very rare cases worldwide, all CDKN2A familial melanoma patients are heterozygous 
for a CDKN2A mutation, yet the normal allele can be epigenetically silenced, resulting in loss of 
heterozygosity (Castellano & Parmiani, 1999). We first investigated the expression of p16 protein, the 
product of CDKN2A, in the melanocyte cultures at early (≤8) versus late (≥9) passage, to determine the 
impact of each of the three CDKN2A mutations and possibly LOF MC1R variants, and to rule out 
epigenetic silencing over time in culture. By Western blot analysis, we detected p16, and phospho (p)-Rb, 
the inactive form of Rb, given that p16 activates Rb by inhibiting its phosphorylation, in a panel of 
melanocyte cultures listed in Table 1. Controls were melanocyte cultures expressing wild-type CDKN2A 
and MC1R, or a MC1R LOF allele, as well as two previously described rare melanocyte cultures, 13a 
(Hmel-16-1 ) and 14a (Hmel-16-II) with two mutant CDKN2A alleles (Gruis et al., 1995; Sviderskaya et 
al., 2003). As reported earlier, 13a lacked p16, while 14a expressed high p16 levels (Fig. 1) (Gruis et al., 
1995; Huot et al., 2002). The remaining cultures expressed p16 at different levels, and CDKN2A 32ins24 
mutation carriers 11a and 12a, expressed p16 as two bands, with the higher molecular weight band 
representing the product of the mutant allele (Fig. 1). The levels of p16 protein did not correlate with 
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MC1R genotype.  Expression of p16 remained detectable in late passage melanocytes (Fig. 1b), which 
approached replicative senescence, as depicted by marked prolongation of doubling time and increase in 
the percent of β-galactosidase-positive melanocytes (Fig. 2, 3).  These results suggest that CDKN2A is not 
epigenetically silenced with increased passage in culture.  
The level of p-Rb, which is reduced by p16, varied among the different cultures, possibly due to 
differences in their proliferation rate, passage number, and overall genetic background (Fig. 1a). In early-
passage melanocytes, 24 h after addition of fresh growth medium, the levels of p-Rb induced by 
mitogens, and representing inactive Rb, were highest in 3a and 5a, and in p16-null 13a melanocytes (Fig. 
1a). There seemed to be an inverse correlation between p16 and p-Rb levels, particularly in late passage 
cultures (Fig. 1b, Fig. S1). The levels of p-Rb were lowest in late-passage cultures 11a, 12a, 14a, 15a, 
20a, and 23a with the highest levels of p16, and low or no proliferation capacity, as depicted below in Fig. 
1b, 2, 3, and Fig.S1. Late passage p16-null 13a also expressed very low levels of p-Rb, possibly due to 
the inhibitory effect of other cyclin/cdk inhibitors. These results suggest that p16 mutation carriers 
continue to express functional p16 protein and/or other cyclin/cdk inhibitors with increased passage in 
culture.  
Similar to p16, p15, the product of CDKN2B, adjacent to CDKN2A, functions as a cyclin-D-
CDK4/6 inhibitor, and promotes melanocyte senescence (Hannon & Beach, 1994; McNeal et al., 2015). 
We examined the levels of p15 in the above melanocyte cultures (Fig. 1b) (McNeal et al., 2015). The p16-
null 13a expressed the highest levels of p15. Densitometry analysis revealed an inverse correlation 
between p16 and p15 levels in 7 of 20 (35%) cultures, mostly in 15a and 23a followed by 3a, 18a and 25a, 
which expressed the highest levels of p16 and low levels of p15, and in 19a and 21a, which expressed 
very low levels of p16 and relatively high levels of p15 (Fig. S1), suggesting a compensatory role of these 
two CDK inhibitors.  
To elucidate if CDKN2A mutations might reduce MC1R activity, we measured the increase in the 
levels of cyclic adenosine monophosphate (cAMP), the second messenger for MC1R, in response to 
treatment with its agonist α-MSH (Suzuki et al., 1996). Melanocytes expressing V126D or 5’UTR-34>T 
mutation, even those co-expressing a LOF MC1R allele, responded to 10 nM α-MSH with significant 
increase in cAMP levels, which differed among cultures due to donor variability and differential 
expression of genes that affect MC1R expression or its cAMP pathway, as reported earlier (Table S1) 
(Kadekaro et al., 2010). We have reported that treatment of melanocytes expressing functional MC1R 
with α-MSH enhanced their capacity to repair UV-induced CPD, the major form of DNA photoproducts 
(Kadekaro et al., 2010). We found that V126D mutant melanocytes, similar to their wild-type 
counterparts, responded to α-MSH with enhanced repair of UV-induced CPD, further confirming that the 
CDKN2A mutations investigated did not inhibit MC1R activity (Fig. S2). 
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Comparison of population doubling time and capacity for replicative senescence of different 
melanocyte cultures: 
Given the significance of p16 as a CDK inhibitor and regulator of senescence, and MC1R 
signaling in regulating melanocyte proliferation (Sun et al., 2007; Swope, Medrano, Smalara, & Abdel-
Malek, 1995), we compared the proliferation capacity of the melanocyte cultures as a function of passage 
in culture by determining their respective doubling times. In general, almost all melanocytes showed 
gradual reduction in their proliferation rate, evidenced by prolonged doubling time with increased passage 
number (Fig. 2). Exceptions were11a and 12a, co-expressing 32ins24 CDKN2A mutation and a LOF 
MC1R variant that had the lowest proliferation capacity and longest doubling times even at early passage 
(5 and 4, respectively) (Fig. 2), which limited their use for further experiments. In contrast, 21a 
maintained a high proliferation rate and the same doubling time (4.1 days) at passages 9 and 13 (Fig. 2). 
The doubling time did not seem to correlate with donors’ age. For example, at early passages (3-7), the 
doubling times of 6a and 17a, from donors age 42 and 43, were comparable to those of 8a and 22a, and 
shorter than that of 18a, from donors in their twenties (Fig. 2, Table 1). The two cultures 13a and 14a, 
expressing two mutant CDKN2A alleles, failed to proliferate in the routine melanocyte growth medium 
and  required a highly enriched growth medium in order to proliferate, as previously reported 
(Sviderskaya et al., 2003). In our enriched medium, the doubling time of 13a increased from 5 days at 
passage 14 to 16.8 days at passage 21, and that of 14a was maintained at 11.7 days at passages 17 and 20 
(Fig. 2).  Unfortunately, early passages of these two cultures are not available. As reported (Fung et al., 
2013; Sviderskaya et al., 2003), p16-null 13a exhibited reduction of proliferation rate under highly 
enriched culture conditions, albeit at a higher passage than their heterozygous or wild-type counterparts, 
suggesting that p15, and possibly other CDK inhibitors, compensate for p16 loss and drive the senescence 
program. 
The cultures varied in their doubling times independently of CDKN2A or MC1R genotype, with 
the exception of 11a and 12a (Fig. 2), and this was corroborated by cell cycle analysis (Table S2). These 
variations are due to differential expression of other genes that regulate proliferation rate in different 
donors.  Interestingly, the two wild-type cultures 17a and 18a, but not 15a, underwent a sharp decline in 
proliferation by passages 7 and 9, respectively. The number of population doublings of the different 
melanocyte cultures until they became quiescent ranged between a minimum of 8-11 for10a -12a, and 
18a, to ≥19 for 2a-8a, 15a, and 21a (Table S3), which correlated in most cases with their early doubling 
time. These results suggest that expression of V126D or 5’UTR-34G>T CDN2A mutation, with or 
without LOF allele did not have an obvious impact on the proliferative capacity of melanocytes, known to 
be regulated by the crosstalk of multiple signaling pathways (Swope et al., 1995). 
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Senescence is a state of permanent growth arrest that is reached after cells exhaust their 
proliferation capacity, and is primarily regulated by p16 in melanocytes (Haferkamp et al., 2009; 
Sviderskaya et al., 2002). In light of the results in Fig. 2, we investigated whether the marked reduction in 
proliferation with passage in culture was due to replicative senescence. For that, we compared the percent 
of senescent melanocytes at different passages, using β-galactosidase staining (Fig. 3) (Dimri et al., 
1995). Consistent with the doubling time data (Fig. 2), the percent of β-galactosidase-positive 
melanocytes and the intensity of staining increased with passage in culture, regardless of their CDKN2A 
or MC1R genotype. An exception was 21a, which had less than 12% of melanocytes positive for β-
galactosidase at passage 9 (data not shown), consistent with their persistently high proliferation rate (Fig. 
2). Increased β-galactosidase staining was even evident in 13a and 14a, albeit at a much higher passage 
than other cultures. The percent of β-galactosidase-positive cells increased by about 30% in 13a and 14a 
from passages 18 and 17 to passages 22 and 21, respectively, further confirming that other effectors, such 
as p15 and p21 can compensate for loss of p16 function (Fung et al., 2013; Sviderskaya et al., 2003). 
Even neonatal melanocytes (26n and 29n) showed a remarkable increase in β-galactosidase-positive 
staining with increased passage (22 and 14, respectively) in culture. We conclude that carriage of 
mutations in CDKN2A even with co-expression of a MC1R LOF variant does not abrogate replicative 
senescence or extend the proliferative capacity of melanocytes.  
DNA damage response to UV: 
Solar UV is a main etiological factor for melanoma, and UV signature mutations are evident in 
melanoma tumors (Hodis et al., 2012). The role of MC1R in the UV response of melanocytes is well-
documented, and the possible role of p16 in regulating DNA repair has also been reported (Abdel-Malek 
et al., 2014; Cao et al., 2013; Sarkar-Agrawal et al., 2004). To investigate the DNA damage response to 
UV of melanocyte cultures with different CDKN2A  and MC1R genotypes (in Table 1), we compared 
their responses to irradiation with 75 mJ/cm2 UV, a sub-lethal dose that induced substantial DNA 
photoproducts .   DNA damage induced by UV results in cell cycle arrest to allow for DNA repair 
(Kastan, Onyekwere, Sidransky, Vogelstein, & Craig, 1991; Lo et al., 2005); Barker et al., 1995). All 
cultures tested, regardless of genotype, including 13a and 14a, responded to the above UV dose with 
prolonged doubling time, due to transient G1 and G2 arrest (Fig. 4, Table S2), suggesting their ability to 
sense DNA damage. 
 Since V126D is  a common CDKN2A mutation in melanoma-prone families in the U.S.A. 
(Goldstein et al., 2001), we further compared the DNA damage response to UV of 4a and 5a to that of 
13a, 17a, and 21a, using Western blot analysis for the stress-activated MAP kinases JNK and p38, p53 
and its downstream target GADD45α, all known to be activated by UV, and p-Rb, which is inhibited by 
UV (Fig. 5, Fig. S1) (Medrano, Im, Yang, & Abdel-Malek, 1995; M. L. Smith et al., 1996; Tada, Pereira, 
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Beitner-Johnson, Kavanagh, & Abdel-Malek, 2002). All five cultures had similar responses, regardless of 
their genotype. Figure 5a, b, and c represent the responses of 5a, and Fig. S3 represents those of 13a. 
Phosphorylation, i.e. activation, of the stress-induced MAP kinases JNK and p38, was evident as early as 
30 min post UV, and increased for at least 4 h (Fig. 5a). The p53 protein increased time-dependently for 
at least 24 h, beginning 3 h post UV (Fig. 5b). The levels GADD45α also increased in response to UV, 
indicating p53 transactivation (Fig. 5c, Fig. S3). In the control unirradiated groups, addition of fresh 
medium increased the levels of p-Rb time-dependently, indicative of Rb inactivation by mitogens, while 
irradiation with UV reduced p-Rb, consistent with cell cycle arrest (Fig. 4, Fig. 5b). The increase in p-Rb 
in the unirradiated control groups was markedly less in the late, as compared to early passage cultures, 
consistent with reduced proliferation in the former (Fig 5b). These findings demonstrate that mutations in 
CDKN2A, even complete loss of p16, do not inhibit the above responses of melanocytes to UV. 
The DNA damage resp nse to UV involves activation of DNA repair to maintain genomic 
stability (Cimprich & Cortez, 2008). We compared repair of CPDs in 2a, 5a, 7a, 13a, and 16a, and found 
substantial DNA repair, with only 28-44% of mean fluorescence of CPDs remaining at 48 h, as compared 
to 3 h post UV (Fig. 5d). These results further confirm that a mutantCDKN2A allele, even lack of p16 and 
co-expression of a MC1R LOF variant, does not impair the capacity of melanocytes to repair DNA 
photoproducts. 
Irradiation of melanocytes with UV results in the rapid generation of hydrogen peroxide (Song et 
al., 2009). Previous reports indicated that p16 is critical for reduction of oxidative stress ( (Jenkins et al., 
2011).  However, exposure of melanocytes with different CDKN2A and MC1R genotypes to 90 mJ/cm2 
UV resulted in increased levels of hydrogen peroxide, which reached a maximum at 60 min in all the 
cultures tested (Table S4). The variability in basal and UV-induced hydrogen peroxide levels among the 
cultures with different CDKN2A or MC1R genotype can be attributed to donor variability and differential 
expression of genes that regulate the antioxidant defenses.  
In summary, using primary melanocyte cultures that naturally express a CDKN2A mutation with 
or without a MC1R LOF allele, and multiple functional assays, we found that these melanocytes do not 
markedly differ in their in vitro behavior from their wild-type counterparts, and respond appropriately to a 
single dose of UV. These findings confirm that malignant transformation of CDKN2A mutant 
melanocytes requires additional hits, such as repetitive UV exposure, loss of p15, or somatic mutations 
facilitated by expression of MC1R LOF variant(s) (Robles-Espinoza et al., 2016). It would have been very 
informative to compare the genome of melanoma tumors from the same mutation carriers to that of their 
premalignant melanocytes, but none of those carriers had a melanoma at the time of skin biopsy. Based 
on the reports that CDKN2A germline mutations alter global gene expression in fibroblasts and 
keratinocytes (Fan et al., 2013; Puig-Butille et al., 2014), it is conceivable that these mutations, which are 
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not exclusively melanocyte-autonomous, result in an aberrant microenvironment, which is conducive for 
genomic instability of melanocytes.  Fortunately, we established primary keratinocyte and fibroblast 
cultures from the biopsies of donors listed in Table 1. This will enable us to conduct future experiments to 
determine the impact of CDKN2A mutations on the secretome of keratinocytes and fibroblasts, and to 
investigate the interactions of these cells with melanocytes in the context of a 3D cultured skin model.  
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FIGURE LEGENDS: 
Figure 1. Detection of p16, p-Rb, and p15 in melanocytes with different CDKN2A and MC1R 
genotypes using Western blot analysis. In (a), p16 and p-Rb were detected in early-passage (≤8) 
cultures. Bands 1a-4a, 7a, 8a, 11a, 12a, 17a, and 18a were detected on the same membrane; 5a, 9a, 10a, 
and 21a were detected on a second membrane, and 6a, 13a, 14a, and 23a were detected on a third 
membrane. In (b), p16, p-Rb and p15 were detected in late-passage (≥9) cultures. Actin was used as 
loading control.  +/+= wild-type; -/-= expression of 2 mutant CDKN2A alleles; R/+=heterozygous for a 
red hair (R) LOF MC1R allele; R/R=homozygous or compound heterozygous for 2 R LOF MC1R alleles; 
R/r= compound heterozygous for a LOF variant and the moderate V60 allele;  p/+= heterozygous for the 
pseudoallele V92M MC1R variant. 
Figure 2. Effect of passage in culture on the doubling time of melanocyte cultures with different 
CDKN2A and MC1R genotypes. The star symbol denotes that the calculated doubling time exceeded 55 
days.   
Figure 3. Comparison of the percent of β-galactosidase-positive melanocytes with different 
CDKN2A and MC1R genotypes at early versus late passage in culture. Each bar represents the mean 
of at least 500 melanocytes ± SEM. *= Statistically different from the earlier passage(s) at p<0.05, as 
determined by ANOVA, followed by SNK. The upper panels represent light microscopic views of 15a, as 
they proliferated at a high rate in early passage (in a), and when they reached replicative senescence at 
passage 17 (in b).  
Figure 4. Effect of UV exposure on the doubling time of melanocyte cultures with different 
CDKN2A and MC1R genotypes. Melanocytes were irradiated with UV and the doubling time 
determined as described in Materials and Methods. The star symbol denotes that melanocytes failed to 
show significant recovery from the UV-induced growth arrest by the end of the experiment (10 days post 
UV).    
Figure 5. Expression of p-JNK, p-p38, p-Rb, p53, and GADD45α in response to UV, as depicted by 
Western blot analysis, and the repair of CPD, by melanocytes with different CDN2A and MC1R 
genotypes. The presented data were obtained using cell lysates derived from 5a melanocytes. Panel (a) 
represents the time-dependent expression of p- and total JNK and p- and total p38. Panels (b) and (c) 
represent expression of p53, p-Rb, and GADD45α in early- vs. late- passage (6 and 13, respectively). 
Vinculin and actin were used as loading controls. Similar results were obtained with 4a, 13a, 17a and 21a. 
(d) represents induction (3h) and repair (48 h post UV) of CPD in melanocytes with different genotypes. 
Each data point is the mean of 3-5 determinations ± SEM. *= Statistically different from the respective 3 
h time point at p<0.05, as determined by ANOVA followed by SNK. 
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Cell 
Strain 
Age Gender 
CDKN2A  
Genotype 
MC1R 
Genotype 
1a 28 M V126D/+ +/+ 
2a 20 F V126D/+ +/+ 
3a 31 F V126D/+ D294H/+ 
4a 18 M V126D/+ D294H/+ 
5a 35 F V126D/+ R160W/+ 
6a 42 M V126D/+ R160W/R151C 
7a 24 M 5'UTR-34G>T/+ D294H/+ 
8a 21 M 5'UTR-34G>T/+ R160W/+ 
9a 18 M 5'UTR-34G>T/+ R160W/+ 
10a 22 M 5'UTR-34G>T/+ V60L/T314T 
11a 32 F 32ins24/+ R160W/V60L 
12a 22 M 32ins24/+ R160W/+ 
13a ? M 266_244del19 +/+ 
14a ? ? M53T/D108N R151C/+ 
15a ? F +/+ +/+ 
16a 38 F +/+ +/+ 
17a 43 F +/+ +/+ 
18a 28 F +/+ +/+ 
19a 42 F +/+ +/+ 
20a ? ? +/+ V92M/+ 
21a 26 F +/+ D294H/+ 
22a 21 F +/+ R151C/+ 
23a 40 F +/+ R160W/+ 
24a ? F +/+ R151C/V92M 
25a ? ? +/+ R160W/D294H 
26n NHM M +/+ R160W/D294H 
27a 23 M +/+ R151C/R151C 
28a 13 M +/+ R160W/R160W 
29n NHM M +/+ R163Q/+ 
 
Table 1. : List of primary melanocyte cultures that were established and used in this study. NHM= neonatal human 
melanocytes; a=adult, and n=neonatal melanocytes; F-female; M=male; +/+=wild-type 
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Figure S1. Densitometry analysis of Western blot bands shown in Fig. 1.  Densitometry of p16 and p-
Rb bands in early passage cultures shown in Fig. 1a is presented in panels (a) and (b). Densitometry of 
p16 p-Rb and p15 in late passage cultures, shown in Fig. 1b are presented in panels (c), (d) and (e). 
 
Figure S2. Enhancement of CPD repair by α-MSH treatment in melanocytes heterozygous for 
CDKN2A V126D mutation and a LOF MC1R. Melanocytes were treated with 0 or 10 nM α-MSH, 
irradiated with UV, harvested and stained for CPD 48 h post UV, as described in Kadekaro et al., 2010. 
Each data point represents the mean CPD fluorescence of 3-5 determinations ± SEM. *= statistically 
different from the respective UV group at p<0.05 as determined by ANOVA, followed by SNK. 
 
Figure S3. Western blot analysis of phospho-  JNK, p38, and Rb, and of p53 and GADD45α in UV- 
versus unirradiated p16-null 13a melanocytes. 
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Cell 
Strain 
CDKN2A 
Genotype 
MC1R 
Genotype 
% of Control 
± SEM 
1a, P3 V126D/+ +/+ 228.3 ± 3.0 
2a, P8 V126D/+ +/+ 390.3 ± 2.6 
3a, P4 V126D/+ D294H/+ 201.1 ± 1.9 
4a, P8 V126D/+ D294H/+ 152.6 ± 4.5 
5a, P8 V126D/+ R160W/+ 543.0 ± 1.3 
6a, P13 V126D/+ R160W/R151C 148.9 ± 3.0 
7a, P7 5'UTR-34G>T/+ D294H/+ 223.2 ± 4.1 
13a, P18 266_244del19 +/+ 206.8 ± 1.1 
14a, P18 M53T/D108N R151C/+ 223.0 ± 1.0 
15a, P? +/+ +/+ 338.2 ± 4.2 
17a, P2 +/+ +/+ 235.0 ± 2.9 
18a, P? +/+ +/+ 446.0 ± 3.7 
21a, P12 +/+ D294H/+ 336.4 ± 3.1 
23a, P2 +/+ R160W/+ 447.0 ± 3.0 
 
Table S1. Stimulation of cAMP formation in melanocytes in response to treatment with 10 nM α-MSH. Each data 
point is the mean of 3 determinations ± SEM. 
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Cell 
Strain 
CDKN2A  
Genotype 
MC1R 
Genotype 
Time 
point 
G0-G1 S G2-M 
Mean Mean Mean 
1a, P4 V126D/+ +/+ 0h 79.1 0.2 17.6 
      24h 68.9 10.0 16.2 
      48h 73.0 1.5 20.1 
2a, P6  V126D/+ +/+ 0h 90.3 0.1 6.5 
      24h 89.3 0.6 4.9 
      48h 76.8 3.5 13.1 
3a, P4 V126D/+ D294H/+ 0h 90.0 0.3 6.3 
      24h 88.2 4.6 5.2 
      48h 63.2 11.0 23.0 
      72h 76.5 5.5 16.2 
      UV 0h 90.0 0.3 6.3 
      UV 24h 91.9 0.3 6.2 
      UV 48h 92.1 0.4 5.9 
      UV 72h 84.0 5.7 8.1 
4a, P7 V126D/+ D294H/+ 0h 88.0 0.2 9.3 
      24h 80.1 10.7 7.9 
      48h 58.7 9.6 28.5 
5a, P10 V126D/+ R160W/+ 0h 83.6 0.6 13.5 
      24h 80.7 7.0 10.2 
      48h 58.4 10.7 27.1 
7a, P4 5'UTR-34G>T/+ D294H/+ 0h 85.5 0.4 11.7 
      24h 75.5 12.3 10.1 
      48h 82.0 2.6 13.2 
8a, P4 5'UTR-34G>T/+ R160W/+ 0h 81.9 1.7 13.9 
      24h 84.1 6.0 8.7 
      48h 52.8 14.5 30.6 
15a, P12 +/+ +/+ 0h 71.7 0.8 21.2 
      24h 67.1 9.1 16.9 
      48h 46.5 8.6 34.5 
      72h 49.1 10.7 30.8 
      UV 0h 71.7 0.8 21.2 
      UV 24h 71.8 1.2 21.8 
      UV 48h 70.7 1.6 21.3 
      UV 72h 58.9 8.7 24.4 
 
Table S2. Comparison of the cell cycle profiles of melanocytes with different CDKN2A and MC1R 
genotypes, with or without UV irradiation. Each data point is the mean of at least 3 different 
determinations. All SEM were less than 10% of the respective mean. 
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Cell 
Strain 
CDKN2A 
Genotype 
MC1R 
Genotype 
Latest 
Passage 
Population 
Doubling 
1a V126D/+ +/+ 11 14.3 
2a V126D/+ +/+ 14 23 
3a V126D/+ D294H/+ 14 25 
4a V126D/+ D294H/+ 13 19 
5a V126D/+ R160W/+ 15 27 
6a V126D/+ R160W/R151C 16 25.3 
7a 5'UTR-34G>T/+ D294H/+ 14 20 
8a 5'UTR-34G>T/+ R160W/+ 10 25.7 
9a 5'UTR-34G>T/+ R160W/+ 11 15 
10a 5'UTR-34G>T/+ V60L/T314T 10 11 
11a 32ins24/+ R160W/V60L 9 8 
12a 32ins24/+ R160W/+ 12 10 
15a +/+ +/+ 15 23.8 
17a +/+ +/+ 7 13 
18a +/+ +/+ 9 11 
21a +/+ D294H/+ 14 28 
23a +/+ R160W/+ 10 13 
28a +/+ R160W/R160W 9 14 
 
Table S3.  Comparison of the cell cycle profiles of melanocytes with different CDKN2A and MC1R 
genotypes, with or without UV irradiation. Each data point is the mean of at least 3 different 
determinations. All SEM were less than 10% of the respective mean. 
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Cell 
Strain 
CDKN2A  
Genotype 
MC1R 
Genotype 
Basal H2O2 UV-induced H2O2 % 
increase (pmol/ml/106 cells) (pmol/ml/106 cells) 
1a V126D/+ +/+ 57.6 ± 8.4 180.1 ± 4.4 313 
2a V126D/+ +/+ 40.4 ± 3.1 103.1 ± 11.7 255 
3a V126D/+ D294H/+ 34.7 ± 6.7 86.1 ± 6.4 248 
4a V126D/+ D294H/+ 63.9 ± 0.5 125.8 ± 9.7 197 
5a V126D/+ R160W/+ 47.8 ± 2.9 112.6 ± 19.9 236 
7a 5'UTR-34G>T/+ D294H/+ 46.3 ± 8.5 229.6 ± 15.7 496 
15a +/+ +/+ 24.0 ± 1.1 57.5 ± 4.8 239 
23a +/+ R160W/+ 57.7 ± 8.8 147.3 ± 7.1 255 
24a +/+ R151C/V92M 56.4 ± 9.3 195.3 ± 5.9 346 
 
Table S4.  Comparison of basal and UV-induced H2O2 levels of melanocytes with different CDKN2A 
and MC1R genotypes. Data represent hydrogen peroxide levels generated 60 min post irradiation with 90 
mJ/cm
2 
UV.  Each value is the mean ± SEM of 3 different determinations. 
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